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Visual Abstract
Significance Statement
The protein tau is highly expressed in neurons and is involved in maintaining neuronal structure. In diseases
such as Alzheimer’s disease (AD), tau can form oligomers, which consist of tau molecules joined together.
There is growing evidence that these tau oligomers are toxic to neurons, although their precise actions are
still being characterized. We have taken the approach of introducing structurally-defined tau-441 oligomers
into neurons via the recording electrode (a method previously published by Kaufmann et al., 2016). This
method allowed us to provide detailed characterization of the concentration and time-dependent actions of
tau oligomers on neuronal properties. We have found that tau interferes with the action potential wave form,
modifies synaptic transmission and can block events that probably underlie memory storage.
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Tau is a highly soluble microtubule-associated protein that acts within neurons to modify microtubule stability.
However, abnormally phosphorylated tau dissociates from microtubules to form oligomers and fibrils which
associate in the somatodendritic compartment. Although tau can form neurofibrillary tangles (NFTs), it is the
soluble oligomers that appear to be the toxic species. There is, however, relatively little quantitative information
on the concentration-dependent and time-dependent actions of soluble tau oligomers (oTau) on the electrophys-
iological and synaptic properties of neurons. Here, whole-cell patch clamp recording was used to introduce
known concentrations of oligomeric full-length tau-441 into mouse hippocampal CA1 pyramidal and neocortical
Layer V thick-tufted pyramidal cells. oTau increased input resistance, reduced action potential amplitude and
slowed action potential rise and decay kinetics. oTau injected into presynaptic neurons induced the run-down of
unitary EPSPs which was associated with increased short-term depression. In contrast, introduction of oTau into
postsynaptic neurons had no effect on basal synaptic transmission, but markedly impaired the induction of
long-term potentiation (LTP). Consistent with its effects on synaptic transmission and plasticity, oTau puncta
could be observed in the soma, axon and in the distal dendrites of injected neurons.
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Introduction
Tau is a native protein usually associated with microtu-
bules and is key to maintaining cellular morphology, par-
ticularly in neuronal axons (Tracy and Gan, 2018). Tau is
also expressed in the dendrites and is involved in some
forms of synaptic plasticity (Regan et al., 2015). Under
physiological conditions, the phosphorylation level of tau
protein is regulated by the equilibrated action of kinases
and phosphatases. However, dysfunctional states can
induce hyperphosphorylation causing tau to disassociate
from microtubules, altering their stability (Qiang et al.,
2018), with the now free monomeric tau protein prone to
aggregation (Avila et al., 2006). The hyperphosphorylated
tau monomers initially polymerise to form soluble oligom-
ers. These -sheet-rich oligomers can then further aggre-
gate into protofibrils, fibrils and neurofibrillary tangles
(NFTs). Although NFTs are major histopathological hall-
marks of neurodegenerative tauopathies (Nelson et al.,
2009), there is strong evidence that the soluble oligomers
are the toxic species and play a more important role in
disease pathology. Previous studies have shown that tau
overexpression leads to neuronal loss, synaptic and be-
havioral dysfunction without NFT accumulation (Lee et al.,
2001; Wittman et al., 2001; Tanemura et al., 2002; Tate-
bayashi et al., 2002; Andorfer et al., 2003; Spires et al.,
2006; Yoshiyama et al., 2007; Cowan et al., 2010). Fur-
thermore, the introduction of tau oligomers (oTau), either
extracellularly or via injection into the brain of wildtype
rodents induces synaptic, mitochondrial and memory
dysfunction (Fá et al., 2016; Ondrejcak et al., 2018), con-
sistent with the hypothesis that oTau are the drivers of
toxicity. Alongside the direct effects of oTau, studies have
also demonstrated its role in mediating the pathogenesis
of other aggregating proteins including amyloid  and
-synuclein (Castillo-Carranza et al., 2015 and Teravskis
et al., 2018, respectively).
Many previous electrophysiological investigations of
the effect of oTau on neuronal properties have been
conducted using extracellular application of oTau or
transgenic tauopathy mouse models, where mutant forms
of tau protein, that are prone to aggregate, are overex-
pressed. In such studies, oligomeric tau has been shown
to alter the intrinsic excitability of neurons and modulate
short-term and long-term plasticity (Tamagnini et al.,
2017; Mondragón-Rodríguez et al., 2018; and Hoover
et al., 2010; Rocher et al., 2010). For example, Ondrejcak
et al. (2018) suggested a postsynaptic action of oTau by
showing that administrating intracerebroventricular injec-
tions, of either recombinant aggregated tau protein or tau
protein isolated from human Alzheimer’s disease (AD)
patients, inhibited hippocampal long-term potentiation
(LTP) with no effect on paired-pulse ratio. Dissociated tau
protein (from viral expression) has also been shown to
localize in presynaptic nerve terminals, binding to synap-
tic vesicles, reducing their mobilization, fusion rate and
rate of recycling (Zhou et al., 2017).
In our study, in vitro electrophysiology (whole-cell patch
clamp recording), together with detailed quantitative anal-
yses has been used to fully characterize the effects of
introducing (oTau) directly into cortical neurons. This ap-
proach has allowed the evaluation of the direct effects of
oTau within a neural network that is free from tau pathol-
ogy apart from the recorded neuron. Unlike previous stud-
ies, this has allowed the delineation of time-dependent
and concentration-dependent effects of oTau. Moreover,
measuring the electrophysiological and synaptic proper-
ties of each neuron immediately after whole-cell break-
through acts as an internal control for each recording.
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Using this approach, oTau can be introduced into either
presynaptic or postsynaptic cells and the effects on syn-
aptic transmission and plasticity measured. Such target-
ing is not possible in studies where oTau is applied via the
extracellular solution as it is difficult to ascertain whether
the observed toxic effects are due to exogenous oTau
affecting cell-membrane integrity or the direct intracellular
effects of internalized oligomers. While the estimated
physiologic concentration of tau protein in neurons is 2
M (Avila, 2010), here, we demonstrate that introduction
of nanomolar concentrations of oTau into hippocampal or
neocortical pyramidal neurons is sufficient to cause sig-
nificant changes in action potential kinetics, impair basal
synaptic transmission and disrupt synaptic plasticity over
a 45- to 50-min timeframe.
Materials and Methods
Protein expression, purification, and characterization
Briefly, Escherichia coli BL21 (DE3) carrying pProEX
plasmids (Promega) coding for wild-type full-length tau-
441 (Uniprot ID: P10636-8) with N-terminal 6xHis and
FLAG tags and cysteine modifications (C291A/C322A/
I260C), (Figure 1) were inoculated into Luria broth (15 ml)
containing ampicillin (100 g/ml) and chloramphenicol (35
g/ml) and incubated at 37°C at 180 rpm overnight. The
purpose of the cysteine modifications was to have a
single cysteine residue located outside the microtubule-
binding region that can be specifically labeled by a fluo-
rophore without potentially interfering with the protein’s
functions; this approach has been widely used and shown
to have no detrimental effects (Kumar et al., 2014; Michel
et al., 2014; Shammas et al., 2015; Karikari et al., 2019).
The starter cultures were added to 750-ml fresh LB broth
with ampicillin (100 g ml1) and returned to the shaking
incubator for 90 min. When the OD600 reached 0.6, 0.
5mM isopropyl -D-1 thiogalactopyranoside was added
for 1 h. Samples were centrifuged for 10 min at 4°C at
9800  g. The supernatant was removed, and pellets
washed with 10 mM sodium phosphate pH 7.4 buffer
twice. Pellets were re-dissolved in 10 mM sodium phos-
phate buffer pH 7.4 and stored at –20°C until use. Sam-
ples were purified via immobilized metal affinity
chromatography (IMAC).
Eluted fractions from IMAC were analyzed using 6%
non-denaturing SDS-PAGE gels to determine the highest
yields which were pooled and concentrated using Slide-
A-LyzerTM MINI Dialysis devices (10K MWCO; Thermo
Scientific). Briefly, the devices were washed with 1-ml
sodium phosphate pH 7.4 buffer, the samples added and
centrifuged for 30 min at 2600  g at 4°C. A bicinchoninic
acid assay (#786-570, G-Biosciences) was used to calcu-
late the concentration and where needed the remaining
liquid concentrated with further spins.
Preparation of fluorescently labeled oTau
Purified Tau-441 was treated with 5x molar excess of
tris(2-carboxyethyl)phosphine (TCEP) for 1 h, and then
with 4molar excess of Alexa Fluor-maleimide (#A10254,
Invitrogen) overnight in the presence of sodium phos-
phate buffer pH 7.4. Free fluorophore and reducing agent
were removed by 5  2 h repeat dialysis against 2 l of
dialysis buffer (50 mM Tris HCl, pH 7.5, and 100 mMNaCl)
in a Slide-A-LyzerTM MINI Dialysis device (10K MWCO) at
each step. Non-denaturing SDS-PAGE followed by ultra-
violet light exposure were used to confirm labeling, with
efficiency spectrophotometrically estimated using Beer’s
law and molar extinction coefficient of tau-441. Unlabeled
controls were prepared following the same protocol but
with equal volume of 10 mM sodium phosphate buffer pH
7.4 instead of the maleimide label. The entire labeling
process was performed at room temperature.
Circular dichroism (CD) spectroscopy
CD spectra were collected on unlabeled tau-441 diluted
to 10 M in sodium phosphate buffer pH 7.4. The sample
was loaded in a 1-mm path-length cell and transferred to
a Jasco J-815 CD spectropolarimeter. Ten different spec-
tra were taken on each sample and the average pre-
sented. The analytical conditions were: scan speed 100
nm/min, response time 1 s, data pitch 0.1 nm, and high-
tension voltage 550 V.
Transmission electron microscopy
Formvar/carbon-coated 300-mesh copper grids
(#S162, Agar Scientific) were glow-discharged using the
ELMO system from Cordouan Technologies. Five micro-
liters of labeled or unlabeled tau-441 preparations were
pipetted onto the grid and allowed to bind for 1 min.
Excess samples were removed with a strip of filter paper,
and 5 l of 2% uranyl acetate added for 1 min. After
removing the excess stain with a strip of filter paper, the
grids were imaged using a JEOL-2100F transmission
electron microscope.
Dynamic light scattering
Size distributions of labeled proteins at 1 mg/ml were
measured on a Zetasizer Nano ZS machine (Malvern). Up
to ten repeat measurements were obtained for each sam-
ple. The “number distribution” function was used to com-
pute the percentage size distribution of the particles.
Dot blot
Two microliter aliquots of tau-441 (444 M) dissolved in
intracellular patching solution were spotted onto nitrocel-
lulose membranes, allowed to dry and then blocked with
10% non-fat milk in PBS with 0.05% Tween for 1 h. The
membranes were thereafter washed five times with 10%
Tris-buffered saline (TBS)-Tween and incubated for 2 h
with the primary antibodies diluted in PBS-Tween: T22
(#ABN454, Merck; 1:1000 dilution), HT7 (#MN1000, Ther-
moFisher; 1:1000 dilution), K9JA (#A0024, Dako; 1:5000
dilution). Subsequently, the membranes were re-washed
five times with 10% TBS-Tween and then treated for 2 h
with secondary antibody (anti-rabbit IgG #31450 or anti-
mouse #62-6520, ThermoFisher). Following further washes,
the membranes were developed with an electrochemilumi-
niscent detection kit (BIORAD Clarity Western ECL #170-
5060) and imaged.
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Preparation of tau monomers
oTau was incubated with 5 mM DTT (Sigma-Aldrich) for
30 min at 60°C to induce the breakdown to monomers (Fá
et al., 2016). This conformational change was confirmed
by non-denaturing SDS-PAGE w 6% gels with protein
bands detected after staining with Instant Blue (Expe-
deon). All whole-cell patch experiments involving the in-
troduction of monomeric tau were completed within 3 h of
the monomerization protocol. To confirm that the tau
injected into neurons was monomeric, aliquots from the
same monomerization procedure were mixed with the
intracellular patch solution and resolved on SDS-PAGE
gels as described above.
Electrophysiology
Preparation of hippocampal and neocortical brain slices
All experiments were approved by the local Animals
Welfare and Ethics Board (AWERB) at the University of
Figure 1. Biochemical characterization of recombinant tau-441oligomers. A, Schematic illustration of full-length tau-441 showing the
two N terminus repeats (N1, N2) and the four microtubule-binding repeat domains (R1–R4). To ensure specific labeling with Alexa
Fluor 488 C5-maleimide (AF maleimide) on a single cysteine outside the central core of the microtubule repeat region (R1–R4), the two
native cysteine residues were each modified to alanine (C291A and C322A, shown as black dots below R2 and R3) and a new cysteine
residue introduced at residue 260 (I260C) in R1. This approach has been shown not to have any major effects on the structure and
function of tau (see Materials and Methods). B, Representative negative-stain transmission electron microscopy micrograph showing
that maleimide-labeled oTau has a granular/spherical conformation. The insert shows a single structure at higher magnification. C,
Electron micrograph of negative control (buffer  label only) shows no granular structures. Scale bars  200 and 20 nm for
high-magnification insert. D, Dot blots illustrating the immunoreactivity of oTau that has been dissolved into intracellular recording
solution: lane 1, intracellular recording solution alone; lane 2, intracellular recording solution oTau, which was filtered after the oTau
was added; lane 3, intracellular recording solution filtered before addition of oTau. Filtration after addition of oTau decreased the
presence of oTau as detected with three different antibodies. Thus, in the electrophysiology experiments, the intracellular solution was
filtered before oTau addition. E, CD spectra for oTau showing a prominent negative peak at 208 nm, indicating the presence of 
sheets. There was no difference observed in spectra with or without the cysteine modifications. F, Dynamic light scattering (DLS)
distributions shows that monomeric Tau particles are small with a narrow size distribution (80% particles measuring at 7.5–10 nm).
In contrast, oTau particles are larger and have a much wider size distribution (93% of the particles at 18–32 nm).
Figure Contributions: Emily Hill and Thomas K. Karikari performed the experiments and analyzed the data.
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Warwick. Male BL6 mice (approximately three to four
weeks and P12–P21 for paired-synaptic transmission
studies) were killed by cervical dislocation and decapi-
tated in accordance with the United Kingdom Animals
(Scientific Procedures) Act (1986). Parasagittal hippocam-
pal and neocortical slices (350 M) were cut with a Mi-
crom HM 650V microslicer in cold (2–4°C) high Mg2, low
Ca2 aCSF, composed of the following: 127 mM NaCl,
1.9 mM KCl, 8 mM MgCl2, 0.5 mM CaCl2, 1.2 mM
KH2PO4, 26 mM NaHCO3, and 10 mM D-glucose (pH 7.4
when bubbled with 95% O2 and 5% CO2, 300 mOsm).
Neocortical slices were cut at an angle of 15°, such that
the blade started cutting from the surface (layer 1) of the
neocortex toward the caudal border of the neocortex [to
ensure the integrity of Layer V pyramidal cell (Layer V PC)
dendrites; Kerr et al., 2013]. Slices were stored at 34°C in
standard aCSF (1 mM Mg2 and 2 mM Ca2) for between
1 and 8 h.
Whole-cell patch clamp recording from pyramidal cells
A slice was transferred to the recording chamber, sub-
merged and perfused (2–3 ml/min1) with aCSF at 30°C.
Slices were visualized using IR-DIC optics with an Olym-
pus BX151W microscope (Scientifica) and a CCD camera
(Hitachi). Whole-cell current-clamp recordings were made
from pyramidal cells in area CA1 of the hippocampus and
from thick- tufted Layer V PCs in the somatosensory
cortex using patch pipettes (5–10 M) manufactured from
thick walled glass (Harvard Apparatus). Pyramidal cells
were identified by their position in the slice, morphology
(from fluorescence imaging) and characteristics of the
standard currentvoltage relationship. Voltage record-
ings were made using an Axon Multiclamp 700B amplifier
(Molecular Devices) and digitized at 20 kHz. Data acqui-
sition and analysis were performed using pClamp 10 (Mo-
lecular Devices). Recordings from neurons that had a
resting membrane potential of between –60 and –75 mV
at whole-cell breakthrough were accepted for analysis.
The bridge balance was monitored throughout the exper-
iments and any recordings where it changed by 20%
were discarded. Tau-protein oligomers, from a 22 M
stock (monomer concentration), were added to filtered
intracellular solution containing the following: 135 mM
potassium gluconate, 7 mM NaCl, 10 mMHEPES, 0.5 mM
EGTA, 10 mM phosphocreatine, 2 mM MgATP, and 0.3
mM NaGTP (293 mOsm, pH 7.2) to give a final concen-
tration of either 44, 133, or 444 nM tau-protein oligomers
for CA1 neurons (2, 6, and 20 g/ml tau) and 666 nM for
Layer V PCs (30 g/ml tau). Intracellular solution was
filtered before the addition of tau-protein oligomers.
Stimulation protocols
To extract the electrophysiological properties of re-
corded neurons, both step and more naturalistic, fluctu-
ating currents were injected at 10-min intervals for a
duration of the recordings as in (Kaufmann et al., 2016).
Standard IV protocol
The standard currentvoltage relationship was con-
structed by injecting step currents from –200 pA (CA1
pyramidal cells) and –600 to –400 pA (Layer V PCs)
incrementing by either 50 or 100 pA until a regular firing
pattern was induced (Fig. 2). A plot of step current against
voltage response around the resting potential was used to
measure the input resistance (gradient of the fitted line).
Dynamic I-V protocol
The dynamic-I-V curve, defined by the average trans-
membrane current as a function of voltage during natu-
ralistic activity can be used to efficiently parameterize
neurons and generate reduced neural models that accu-
rately mimic the cellular response. The method has been
previously described (Badel et al., 2008; Harrison et al.,
2015; Kaufmann et al., 2016); for the dynamic-IV com-
puter code, see Harrison et al. (2015). Briefly, a current
wave form, designed to provoke naturalistic fluctuating
voltages, was constructed using the summed numerical
output of two Ornstein–Uhlenbeck processes (Uhlenbeck
and Ornstein, 1930) with time constants fast  3 ms and
slow  10 ms. This current wave form, which mimics the
stochastic actions of AMPA and GABA-receptor channel
activation, is injected into cells and the resulting voltage
recorded (a fluctuating, naturalistic trace). The voltage
trace was used to measure the frequency of action po-
tential firing and to construct a dynamic-I-V curve. The
firing rate was measured from voltage traces evoked by
injecting a current wave form of the same gain for all
recordings (firing rate 2–3 Hz). Action potentials were
detected by a manually set threshold and the interval
between action potentials measured. Dynamic I-V curves
were constructed and used to extract a number of pa-
rameters including the capacitance, time constant, input
resistance, resting membrane potential, spike threshold
and spike onset (Fig. 2; Badel et al., 2008; Kaufmann
et al., 2016). Using these parameters in a refractory ex-
ponential integrate-and-fire (rEIF) model reliably mimics
the experimental data, with a spike prediction of 70–
80% as shown previously (Badel et al., 2008). All analyses
of the dynamic-I-V traces were completed using either
MATLAB or Julia software platforms (Bezanson et al.,
2017).
Synaptic transmission
To measure synaptic transmission between connected
neighboring neocortical thick-tufted Layer V PCs, two to
three simultaneous whole-cell current-clamp recordings
were made in somatosensory cortex (Markram et al.,
1997; Kerr et al., 2013). Recordings were made from
neurons in slices from P12 to P21 mice because unitary
EPSPs have a larger amplitude than unitary EPSPs in
slices from older mice and show marked short-term de-
pression (Reyes and Sakmann, 1999; Kerr et al., 2013)
which can be used to measure the effects of oTau on
release probability. Once synaptic connectivity was de-
tected, six action potentials were evoked in the presyn-
aptic neuron (5 at 20 Hz followed by a single recovery
action potential after a 1 s interval) using 5 ms current
steps. These stimulus trains were separated by 10 s and
repeated for the duration of recordings. The amplitude of
overlapping unitary EPSPs was accurately measured us-
ing voltage deconvolution and reconvolution (Richardson
and Silberberg, 2008; Kerr et al., 2013).
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To measure LTP, whole-cell current-clamp recordings
were made from CA1 hippocampal pyramidal cells in the
presence of 50 M picrotoxin (to block GABAA receptors).
Schaffer collaterals were stimulated with a concentric
bipolar electrode (FHC) every 20 s and after a 15 min
baseline, LTP was induced by -burst stimulation [TBS;
10 trains of 10 stimuli (100 Hz) separated by 100 ms]. The
stimulation strength was set to evoke reliable and robust
synaptic transmission (EPSP amplitude 3 mV) without
producing action potential firing in the postsynaptic cell.
Statistical analysis
Analysis was performed using non-parametric Wil-
coxon rank-sum tests and ANOVAs in GraphPad Prism. In
the text, values are given as mean	 SEM. Mean	 SD are
given in Table 1 and Extended Data Table 1-1.
Immunohistochemistry, localization of tau protein
Alexa Flour 594 hydrazide dye (Invitrogen) was added
to the intracellular solution (0.05 mM final concentration)
to allow cell visualization. CA1 pyramidal neurons injected
with labeled oTau were recorded for a minimum of 20 min
to allow the diffusion of tau protein out of the pipette and
into the cell. The pipette was then carefully removed from
the cell, slices were fixed in paraformaldehyde (PFA; 4%)
overnight at 4°C and washed five times for 5 min in PBS
the next morning. Slices were mounted and fixed using
Vectashield (Vector Labs). A Leica 710 confocal micro-
scope was used for imaging and Zen software for image
processing. A subset of 4 neurons were fully recon-
structed using the Airyscan module (tiled z-stacks con-
sisting of 28 stacks each of 260 z-planes) using a Leica
880 confocal microscope to investigate the distribution of
oTau in the axon and dendrites.
Drugs
Picrotoxin (Sigma) and trans-2-carboxy-5,7-dichloro-4-
phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline
(L689,560; Hello-Bio) were made as stock solutions (1–50
mM) and diluted in aCSF on the day of use.
Results
Production and biochemical characterization of
human oTau
Recombinant full-length human tau-441, the longest
tau isoform expressed in the human central nervous sys-
tem (Fig. 1A), was expressed in E. coli, labeled, oligomer-
ized, and characterized (as demonstrated in Karikari et al.,
2017, 2019). The tau preparation was labeled with Alexa
Fluor 488-C5-maleimide to block the formation of high
molecular-weight aggregates and fibrils and to allow the
tracking of oTau in recorded neurons. The expressed
oTau had a spherical/granular structure, as shown by
negative-stain electron microscopy (Fig. 1B,C). CD spec-
troscopy showed a single negative peak at 208 nm (Fig.
1E), an intermediate between those peaks typical for
monomers and filaments (200 and 220 nm, respectively),
suggesting the presence of -sheet structures (von Ber-
gen et al., 2005, Karikari et al., 2017). The CD spectrum
was similar when the cysteine residues were not mutated
showing that this alteration had little effect on secondary
structure (Fig. 1E). Dynamic light scattering showed that
monomeric Tau had a uniform small size (mean size  8
	 3.2 nm, with 80% of the particles having a size
between 7.5 and 10 nm). In contrast, oTau was larger and
had a wider size distribution with 93% particles mea-
suring between 18 and 32 nm (Fig. 1F). oTau that was
diluted into intracellular recording solution reacted
strongly with the T22 oligomer-preferring antibody (Fig.
1D), thus the tau protein remains in an oligomeric form.
The same oTau preparations also reacted strongly with
HT7 and K9JA antibodies, which bind to the mid-region
and microtubule-binding region tau, respectively (Fig. 1D).
Effects of oligomeric tau on CA1 pyramidal cell
subthreshold electrophysiological properties
Two controls were used in the electrophysiological re-
cording experiments. First, a vehicle solution (sodium
phosphate pH 7.4 buffer), treated with the same labeling
protocol as tau protein, was added to the intracellular
solution (at the same volume as the oTau). Second, to
ensure that the addition of a protein to the intracellular
solution did not produce non-specific effects, bovine se-
rum albumin (BSA) was added to the intracellular solution
(20 M). BSA has a similar molecular-weight to tau mono-
mers and was injected at higher concentration than oTau
(20 M vs 44–666 nM).
The two controls and oTau, each diluted in the intracel-
lular solution, were introduced into hippocampal CA1 py-
ramidal cells via the recording electrode during whole-cell
current-clamp recording. Following the termination of re-
cordings (after 50 min), slices were fixed and the re-
Table 1. Electrophysiological parameters measured for CA1 hippocampal pyramidal cells at time 0 for all experimental
treatments
Vehicle BSA 44 nM oTau 133 nM oTau 444 nM oTau
Parameter Mean SEM SD Mean SEM SD Mean SEM SD Mean SEM SD Mean SEM SD
C (pF) 121.8 	 12.56 	 62.8 125.6 	 14.17 	 34.43 132.55 	 17.65 	 79.43 105 	 8.04 	 44.22 125.3 	 14.31 	 71.55
R in (M) 164.4 	 12.22 	 61.1 183.6 	 21.13 	 52.83 157.89 	 23.01 	 103.55 180.36 	 20.42 	 112.31 176.8 	 4.74 	 23.7
 (ms) 20.72 	 1.75 	 8.75 15.72 	 0.89 	 2.23 16.67 	 1.86 	 8.37 15.24 	 1.40 	 7.7 19.63 	 2.25 	 1.25
E (mV) –67.2 	 1.16 	 5.8 –68.5 	 1.34 	 3.35 –69.63 	 0.91 	 4.10 –66.22 	 1.06 	 5.83 –64.95 	 2.0 	 10
V T (mV) –50.07 	 0.68 	 3.4 –52.69 	 1.26 	 3.15 –54.8 	 0.984 	 4.43 –50.67 	 1.35 	 7.43 –50.92 	 1.49 	 7.45

T (mV) 0.77 	 0.036 	 0.18 0.82 	 0.063 	 0.16 0.97 	 0.15 	 0.68 0.87 	 0.1 	 0.55 0.89 	 0.08 	 0.4
Action potential
Amplitude (mV)
75.8 	 4.87 	 24.35 83.6 	 1.84 	 4.6 86.11 	 1.59 	 7.16 77.91 	 2.82 	 15.51 82.66 	 1.9 	 9.5
Duration (ms) 1.42 	 0.093 	 0.465 1.48 	 0.07 	 0.18 1.28 	 1.31 	 5.90 1.41 	 0.07 	 0.385 1.44 	 0.053 	 0.265
Rise (mV/ms) 249.4 	 30.54 	 152.7 288.4 	 17.8 	 44.5 318.8 	 26.55 	 119.48 252.7 	 23.68 	 130.24 282.11 	 21.85 	 109.25
See Extended Data Table 1-1 for the mean, SEM, and SD for all other recorded parameters.
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corded cells visualized with confocal microscopy. The
presence of oTau could be observed in the somatic com-
partment of recorded neurons (Fig. 2A). Standard and
dynamic IV protocols (Fig. 2B,C) were used to extract
electrophysiological parameters from neurons where dif-
ferent concentrations of oTau (44, 133, and 444 nM),
vehicle or BSA had been introduced. Electrophysiological
parameters were then compared between the first time
point (0–5 min after whole-cell breakthrough) and at 40
min, where the majority of recordings were still stable. At
the initial time point, Kruskal–Wallis tests confirmed that
there were no significant differences in any of the electro-
physiological parameters (resting potential, input resis-
tance, capacitance, time constant, spike threshold, and
spike onset) from neurons injected with the different
agents (n  10 slices for vehicle, n  5 slices for BSA, n
 9 slices for oTau 44 nM, n  11 slices for oTau 133 nM,
and n  10 slices for oTau 444 nM; Table 1). Therefore,
the initial quality of recordings and neural properties were
comparable across all the experimental treatments. Most
of the extracted parameters did not significantly change
over the duration of recordings for cells that had either
been injected with vehicle, BSA, 44 nM, or 133 nM oTau
(Fig. 3A,B). However, there was a significant increase in
input resistance (176.8 	 4.73 to 239.3 	 36.3 m, p 
0.0020) and depolarization of the resting potential (–67.98
	 1.69 mV at 0 min and –61.79 	 1.655 mV, p  0.0494)
measured after 40 min for neurons injected with 444 nM
oTau (Fig. 3C). Consistent with this increase in input
resistance and membrane potential depolarization, there
was also a significant increase in the action potential firing
rate in cells injected with 444 nM oTau (p  0.0254), and
although not reaching overall significance, six out of
seven cells injected with 133 nM oTau also had an in-
creased firing rate.
oTau markedly slows action potential dynamics and
reduces action potential amplitude
The dynamic IV parameter extraction was effective for
all conditions at 0 min (mean spike match of 72.2	 1.7%,
predicted vs experimental data). However, for the cells
with oTau introduced, by 40 min, the model predictions
were unable to accurately match the experimental spike
data (mean spike match of 46.1 	 5.5%) and therefore
was not used to extract parameters at later time points.
To establish why there might have been a fall in spike
match efficiency, we looked at whether there were
changes to the parameters that define the action potential
wave form (amplitude, duration, rate of rise, and decay).
There was no significant difference in any of these param-
eters at time 0 across all of the experimental treatments
using Kruskal–Wallis tests (Table 1). However significant
changes in the action potential wave form were observed
at the 40 min timepoint for all of the concentrations of
oTau (Fig. 4A,B) but were not observed when neurons
were injected with either vehicle or BSA (Fig. 4A,B). For all
three concentrations of oTau (44, 133, and 444 nM), there
was a significant decrease in action potential amplitude,
speed of rise and speed of decay at 40 min compared to
time 0 (Fig. 4B). The time course for these changes in
action potential parameters (amplitude and rate of rise)
were examined for the different concentrations of oTau
(Fig. 4C,D). The effects of 444 nM oTau occurred signifi-
Figure 2. oTau localization in injected neurons and extraction of electrophysiological parameters. A, Micrograph of a labeled
hippocampal CA1 pyramidal cell (red) with oTau (green) present in the cell body. The tau protein is labeled with Alexa Fluor 488
maleimide and the neuron is filled with Alexa Fluor 594 dye. Scale bar  14 m. B, Illustration of the standard I-V protocol used to
extract neural parameters: current steps start from –200 to –300 pA and are increased by 50 pA (top panel) until a regular firing pattern
is induced (bottom panel). Current steps around the resting potential were used to extract the input resistance. C, The dynamic I-V
protocol injects a naturalistic current into the cell (top panel) and the voltage recorded (bottom panel) is used to extract a set of
parameters using the dynamic I-V method and to determine the firing rate. D, Mean ionic current Iion is plotted against membrane
potential (gray). The black line is the dynamic I-V curve generated by the average current at a particular voltage (in 1-mV bins). E, The
negative of Iion/C is then plotted (gray) along with the EIF computational model fit, black line. From this curve a number of subthreshold
parameters can be extracted (such as resting potential E, time constant , and spike-threshold voltage VT).
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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Figure 3. oTau induces little change in sub-threshold electrophysiological parameters until late time points.A, Themembrane-potential response
to naturalistic current injection (left panel) fromahippocampalCA1pyramidal cell injectedwith vehicle at time0 (afterwhole-cell breakthrough, top)
and after 40min of recording (bottom). The inset showsparts of themembrane-potential response at an expanded time base illustrating that there
is no significant change in the voltage response to naturalistic current injection over time. The standard currentvoltage response (right panel) also
does not change during recording.B, The membrane-potential response to naturalistic current injection (left panel) from a pyramidal cell injected
with oTau (133 nM) at time 0 (after whole-cell breakthrough, top) and after 40 min of recording (bottom). The inset shows parts of the membrane
response at an expanded time base illustrating little change in the voltage response to naturalistic current over time although the action potential
amplitude is smaller. Right panel, The standard currentvoltage responses at time 0 and after 40 min. C, The membrane-potential response to
naturalistic current injection (left panel) from a pyramidal cell injected with oTau (444 nM) at time 0 (after whole-cell breakthrough), after 30 and 40
min of recording. There was a depolarization over the time period leading to an increased firing rate at 30 and 40 min. The inset shows parts of
the voltage response at an expanded time base illustrating little change in the electrophysiological properties at 30 min but clear changes at 40
min. Right panel, The standard currentvoltage response at time 0 and after 30 and 40 min. There are clear changes in the standard
currentvoltage response (a marked increase in input resistance) after 40 min of recording (right panels) but not after 30 min.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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Figure 4. oTau significantly changes action potential dynamics. A, Examples of action potential waveforms recorded at time 0 (left
panel) and after 40 min (right panel) from hippocampal CA1 pyramidal cells injected with either vehicle, BSA, or oTau (44, 133, or 444
nM). B, Summaries of the changes in action potential parameters (amplitude, duration, rate of rise, and rate of decay) from recordings
with neurons injected with either vehicle, BSA, or oTau (44, 133, or 444 nM). For each treatment there are two bars with associated
data points (mean values from single recordings). The first bar and associated points are from time 0 and the second bar and
associated points are after 40 min of recording. Amplitude was significantly decreased in all three tested concentrations of tau
between time points 0 and 40 min (44 nM p  0.0039, 133 nM p  0.0020, 444 nM p  0.0028). Action potential width increased
significantly in cells where 444 nM oTau was introduced (p  0.0156). The rate of rise and decay were also altered following
introduction of oTau. Rise was significantly slower for all three concentrations of oTau (44 nM p  0.0641, 133 nM p  0.00054, and
444 nM p  0.002228). However, decay was significantly slower only for 444 nM oTau, p  0.012. C, Left panel shows the relative
change in action potential amplitude plotted against time for cells injected with oTau (44, 133, or 444 nM). Action potential amplitudes
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cantly earlier than for 44 and 133 nM oTau (10 vs 20 min),
characteristic of concentration-dependent effects.
The changes in action potential amplitude and
kinetics do not occur with monomeric tau protein
Given a previous report that some populations of mo-
nomeric tau can readily seed aggregation to form toxic
oligomers (Mirbaha et al., 2018), we decided to investi-
gate whether tau protein monomers can induce changes
in the action potential wave form or whether only oTau is
responsible. Tau monomers (mTau; 444 nM, see Materials
and Methods; Fig. 5A) were injected into hippocampal
pyramidal cells. There was no significant change in the
currentvoltage relationship over time for neurons in-
jected with mTau (Fig. 5B) and no change in action po-
tential amplitude (at 40 min, the mean amplitude was
98.6% of the amplitude at time 0; Fig. 5C). It is therefore
only the oligomeric form of tau that induces the changes
in neuronal electrophysiological properties over a time-
scale of 40 min. However, it is possible that at longer
time scales the monomeric tau may oligomerize and then
start to have effects on neuronal properties.
The changes in action potential wave form cannot
be accounted for by the aggregation of oTau
increasing series resistance
The reduction in action potential amplitude and the
slowing of rise and decay kinetics could be a result of
electrotonic filtering due to an accumulation of oTau ag-
gregates in the tip of the patch pipette increasing series
resistance. This seems unlikely as there was no significant
difference in series resistance between recordings made
with vehicle in the patch pipette and with oTau (Fig. 5D).
There was also no marked change in series resistance
over the length of recordings when either oTau or vehicle
were introduced into cells (Fig. 5D). To provide further
confirmation, we conducted re-patching experiments (as
in Fang et al., 2014; Fig 5E–J). Following whole-cell re-
cording from a pyramidal cell for 20 min with either oTau
(444 nm) or vehicle (control), the electrode was carefully
removed from the cell surface and the cell was then
re-recorded with an electrode which contained intracellu-
lar solution with vehicle (Fig. 5E,J). The changes in action
potential kinetics induced by oTau were still present when
cells were re-patched with pipettes containing intracellu-
lar with vehicle (Fig. 5I,J). The re-patching of cells which
had originally been recorded with vehicle containing in-
tracellular solution had no effect on action potential kinet-
ics or amplitude (Fig. 5F,G). Therefore, the changes in
action potential dynamics were not the result of oTau
accumulating in the patch pipette or at the site of whole-
cell breakthrough.
Introduction of oTau into presynaptic cells markedly
impairs basal synaptic transmission
Given the marked of effects of oTau on action potential
kinetics, the next step was to investigate if oTau introduc-
tion affected synaptic transmission. Due to the low con-
nectivity between hippocampal pyramidal cells, between
1% and 5% (Debanne et al., 2008), the synapses between
pairs of thick-tufted Layer V neocortical PCs were exam-
ined instead. Initially we confirmed that the introduction of
oTau (444 nM) into Layer V PCs had similar effects on
action potential properties to that observed in hippocam-
pal CA1 pyramidal cells. Action potential amplitude was
significantly reduced from 74.45 	 2.13 mV at time 0, to
60.135 	 6.38 mV after 40 min (p  0.0137) in cells where
oTau was injected (n  8; Fig. 6A). There was no signifi-
cant change in the amplitude of action potentials in neu-
rons injected with vehicle (mean of 80.85 	 1.82 mV at 0
min vs 77.87 	 2.08 mV at 40 min, p  0.1337, n  10).
Injection of oTau also significantly increased the input
resistance (from 92.5 	 7.58 M at time 0 to 108.19 	
8.107 M at 40 min, p  0.0446; Fig. 6A) with no differ-
ence following the introduction of vehicle (90.1	 11.95 vs
92.15 	 12.99 M, p  0.672). Because the effects of
oTau were slower in Layer V thick-tufted PCs, presumably
due to their larger size, we used a larger concentration of
oTau (666 nM) so that any changes in the properties of
synaptic transmission occurred within a manageable time
frame. To test whether oTau affected synaptic transmis-
sion, oligomer preparations were introduced into the pre-
synaptic cell and vehicle was introduced into the
postsynaptic cell (Fig. 6C). A train of five action potentials
followed by a recovery action potential (1 s interval; Kerr
et al., 2013; Fig. 5D) was used to test whether Layer V PCs
were synaptically connected. Once the connectivity was
verified, this stimulus was repeated (at an interval of 10 s)
throughout the duration of recordings (up to 50–60
min). For the 1st EPSP, the amplitude and latency were
measured from average EPSPs (Fig. 6E). Because of the
small amplitude of unitary EPSPs (average amplitude
0.6 mV), average EPSPs (between 30 and 50 sweeps)
were evaluated over the following time periods: 0–10,
10–20, 20–30, and 30–40 min. Deconvolution and then
reconvolution enabled the accurate measurement of the
amplitude of individual average EPSPs in the train in most
recordings (Fig. 6F). However, in a small number of re-
cordings the amplitude of the EPSPs in the train were so
small that they could not be accurately resolved and thus
continued
are normalized to the amplitude at time 0. Right panel shows examples of average action potential waveforms recorded at different
time points from neurons injected with either 133 or 444 nM oTau illustrating the change in amplitude. D, Left panel shows the relative
change in action potential rise against time for neurons injected with oTau (44, 133, or 444 nM). The speed of rise has been normalized
to the speed of rise of action potentials recorded at time 0. Right panel shows superimposed and normalized action potential
waveforms illustrating the effects of oTau at 133 and 444 nM on the rate of action potential rise against recording time. P  0.05,
P  0.01, P  0.001.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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these connections were only used for analysis of the 1st
EPSP.
Out of 230 paired recordings, 25 pairs of neurons were
synaptically connected (one in 9.2 pairs). In 10 of the
connected pairs, vehicle was introduced into both the
presynaptic and postsynaptic cells (as a control). In an-
other 10 connections, oTau was introduced into the pre-
synaptic cell and vehicle was introduced into the
Figure 5. Monomeric tau protein does not change action potential dynamics and the accumulation of oTau in the pipette cannot
account for the effects on action potential dynamics. A, Gel showing dimeric tau protein (lane A) and tau protein converted to
monomers (mTau, in lanes labeled B). B, There is no significant difference between currentvoltage responses from a
hippocampal CA1 neurons injected with 444 nM mTau measured at time 0 and after 40 min of recording. C, Top panel shows
examples of action potential waveforms recorded at time 0 and after 40 min of recording from a neuron injected with 444 nM
mTau. The mTau does not change the amplitude or kinetics of the action potential waveform. C, Bottom panel summarizes data
from five neurons, showing that action potential amplitude does not change over time when neurons are injected with 444 nM
mTau. D, The mean series resistance plotted against time for neurons injected with vehicle, BSA, or oTau (44, 133, or 444 nM).
There was no significant difference in series resistance between treatments and the series resistance did not significantly
increase during recordings. E, Diagram illustrating the control re-patching protocol. Pyramidal-cell recordings were made (20
min) with vehicle present in the intracellular solution. The patch-electrode was carefully removed from the cell and then the cell
was re-recorded from using a new patch-electrode also containing vehicle. F, There was no change in action potential amplitude
during the initial recording (at 20 min, action potential amplitude was 102 	 4% of the amplitude at time 0) and after re-recording
with a new electrode (108 	 11% of amplitude at time 0, n  4 neurons). Thus, the re-patching protocol itself does not induce
changes in action potential amplitude. G, Examples of average action potential waveforms from a single recording. H, Diagram
illustrating the test re-patching protocol. Pyramidal cell recordings were made (20 min) with oTau (444 nM) in the intracellular
solution. The patch-electrode was then carefully removed from the cell and the cell was then re-recorded from using a
patch-electrode containing intracellular solution with vehicle. I, In cells injected with oTau (444 nM), action potential amplitude
decreased during the initial recording period (at 20 min, action potential amplitude was 84 	 3.1% of the amplitude at time 0)
and remained depressed following re-recording with a new patch-electrode containing vehicle (81 	 5% of amplitude at time
0, n  3). J, Shows examples of average action potential waveforms from a single re-patching experiment with 444 nM oTau.
These control experiments strongly suggest that the aggregation of oTau in the electrode or in the area around the initial
whole-cell breakthrough does not account for the observed changes in action potential dynamics.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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Figure 6. Protocols for testing the effect of oTau on synaptic transmission between thick-tufted Layer V somatosensory neocortical
neurons. A, Standard I-V relationships recorded from neocortical Layer V PCs using pipettes containing either vehicle (top panels) or
oTau (666 nM, bottom panels). There was no significant change in the I-V relationship over 40 min in cells injected with vehicle,
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postsynaptic cell, and in a further four recordings, oTau
was introduced into the postsynaptic cell and vehicle in
the presynaptic cell. At early time points (0–10 min), there
was no significant difference in the amplitude of the 1st
EPSP in the train (p 0.51) or its latency (p 0.581) when
either vehicle or oTau were introduced into the presynap-
tic cell (mean unitary EPSP amplitude: vehicle 0.75	 0.13
mV; oTau 0.61 	 0.13 mV; latency: vehicle 2.2 	 0.0002
ms, oTau 2.1	 0.0001 ms). When vehicle was introduced
into both the presynaptic and postsynaptic cells, the am-
plitude of the 1st EPSP in the train remained relatively
stable for the duration of recordings (the amplitude of the
1st EPSP after 40–50 min of recording was 90.5	 14% of
the EPSP amplitude at 0–10 min of recording). However,
when oTau was introduced into the presynaptic cell, al-
though the recordings remained stable (mean membrane
potential at time 0, 67.5 	 1.5 mV vs membrane potential
40 min, 62.5 	 1.3 mV), the amplitude of the 1st EPSP in
the train was markedly diminished in seven out of nine of
the recordings. At 40–50 min, the amplitude of the 1st
EPSP was significantly (p  0.034) reduced to 30 	 10%
of the amplitude of EPSPs at 0–10 min (n  9; Fig. 7A,B).
This reduction in EPSP amplitude was not a result of failed
action potential firing in the presynaptic cell, as the small
number of sweeps in which any of the action potentials in
the train failed (46 out of 3900 sweeps, 1.2%) were
excluded from analysis. This indicates that the introduc-
tion of oTau into the presynaptic cell leads to a marked
impairment in synaptic transmission between Layer V
pyramidal neurons that occurs within a short time frame.
The deficits in synaptic transmission are associated
with increased short-term depression
We next examined whether short-term synaptic plastic-
ity was altered by oTau by measuring the degree of
depression induced by firing five action potentials at 20
Hz (50-ms interval). If the reduction in EPSP amplitude
induced by oTau is a consequence of a fall in the proba-
bility of transmitter release, then short-term depression
may be reduced (equivalent to the activation of presyn-
aptic receptors such as adenosine A1; Kerr et al., 2013).
For analysis, the amplitude of EPSPs in the train (2nd to
5th EPSP) were measured relative to the amplitude of the
1st EPSP. In 9 out of 10 recordings (in one recording the
connection was too weak to accurately measure the am-
plitude of the 2nd to 5th EPSPs) with vehicle introduced
into both the presynaptic and postsynaptic cells, there
was little change in the degree of short-term depression
over the duration of the recordings (Fig. 7C,D). There was
a small (but significant) increase in depression as there
was a decrease in the paired-pulse ratio (2nd EPSP/1st
EPSP amplitude) over 40 min (Fig. 7G). In the recordings
(eight out of nine, one connection was too weak to accu-
rately measure) where oTau was introduced into the pre-
synaptic cell, there was an increase in the degree of
short-term depression (Fig. 7E,F). In four out of the eight
connections, there was a failure of transmission: the 2nd
to 5th EPSPs were absent (Fig. 7E). This was not a result
of failed action potential firing, as any failures of presyn-
aptic firing were excluded from analysis (as outlined
above). There was also a significant decrease in the
paired-pulse ratio (1st EPSP/second EPSP), but this was
comparable to the connections with vehicle in presynaptic
and postsynaptic cells. To examine the duration of the
depression, we measured the relative amplitude of the
recovery EPSP, which was evoked 1 s after the train of
action potentials (Fig. 7H). Although there was greater
depression in connections with oTau present in the pre-
synaptic cell, the recovery (amplitude of recovery EPSP/
1st EPSP amplitude) was not different to connections with
vehicle introduced into presynaptic and postsynaptic
cells. This indicates that the additional short-term depres-
sion induced by oTau recovers over the same period as
the depression in control conditions. Therefore, the im-
pairment of synaptic transmission is associated with an
increase in depression and thus differs from the activation
of presynaptic receptors.
Introducing oTau into the postsynaptic cell does not
impair basal synaptic transmission
In four connected pairs of Layer V PCs, oTau was
introduced into the postsynaptic cell with vehicle intro-
duced into the presynaptic cell (Fig. 8A). In these connec-
tions, there was no significant reduction in the amplitude
of the 1st EPSP in the train over time (average EPSP
amplitude after 40 min was 91.8% of the EPSP recorded
at 0–10 min; Fig. 8B,C), and there was little change in
short-term depression over time (Fig. 8D,E). Unlike the
marked effects observed when oTau was introduced into
the presynaptic cell, introduction of oTau into the post-
synaptic neuron did not impair basal synaptic transmis-
sion over the duration of the recordings.
continued
whereas oTau reduced action potential amplitude and increased cell input resistance. B, Micrograph of three Layer V PCs labeled with
Alexa Fluor 488. Recordings were routinely made from three neighboring pyramidal cells to increase the probability of finding
synaptically connected cells. C, Diagram of experimental protocol for synaptically connected pyramidal cells. Top panel, oTau was
introduced into the presynaptic cell and vehicle was introduced into the postsynaptic cell. Bottom panel, For control recordings,
vehicle was introduced into both presynaptic and postsynaptic neurons. D, A train of five action potentials (20 Hz) and one recovery
action potential were evoked in the presynaptic cell with short depolarizing current steps (top) and the resultant EPSPs were recorded
in the postsynaptic cell (bottom). E, Expanded traces of the first action potential (in the train) and the resultant EPSP illustrating the
measurement of 1st EPSP amplitude and latency. F, Method of accurately measuring the amplitude of the 2nd to 5th EPSPs in the
train. EPSPs were averaged (after removing any baseline drift) and then deconvolved. The deconvolved EPSPs were cropped out and
then reconvolved so that individual average EPSPs were not superimposed on the decay of the previous EPSP average. The accuracy
of the deconvolution method was confirmed by reconvolving the EPSPs and comparing the resultant waveforms to the original
untransformed EPSPs.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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Figure 7. Presynaptic oTau impairs synaptic transmission between Layer V PCs. A, The amplitude of the 1st EPSP in the train (relative
to the amplitude of averaged EPSPs over the first 10 min of the recording) plotted against time for synaptically connected pairs with
either vehicle or oTau (666 nM) introduced into the presynaptic cell. There was little change in the amplitude of EPSPs for connections
where vehicle was introduced into presynaptic and postsynaptic cells (over 50 min), but there was a significant decline in the
amplitude of EPSPs when oTau was introduced into the presynaptic cell (control vs tau 30–40 min p  0.0293, 40–50 min p 
0.0344). B, Example of averaged 1st EPSPs at different time points when either vehicle or oTau was introduced into the presynaptic
cell. The EPSPs are averages of 30–50 sweeps and have been deconvolved, cropped and then reconvolved (as outlined in Fig. 6).
C, Graph plotting the amplitude of average EPSPs (relative to the amplitude of the 1st EPSP) against number in the train for 0–10 min
of recording and for 30–40 min of recording, where vehicle was introduced into both presynaptic and postsynaptic cells. There was
a small but significant increase in depression between time 0 and 30–40 min for the 2nd EPSP (p  0.0316) and the 5th EPSP (p 
0.0409) in the train. D, Example EPSP waveforms from a single recording when vehicle was introduced into both the presynaptic and
postsynaptic cells. Averages were constructed at 0–10 min (left panel) and at 30–40 min (right panel) and are normalized so the
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Postsynaptic oTau injection impairs LTP
Although introduction of oTau into the postsynaptic
neuron had no effect on basal synaptic transmission it
may modulate synaptic plasticity, as it has been sug-
gested that the inhibitory effects of extracellular oTau on
LTP are postsynaptic (Ondrejcak et al., 2018). To investi-
gate this possibility, we made whole-cell current-clamp
recordings from CA1 hippocampal neurons and stimu-
lated Schaffer collaterals (Fig. 9A). We took this approach
as access to presynaptic neurons was not required and it
is much more straightforward to carry out the experiment
in hippocampal slices. oTau, vehicle, or mTau was intro-
duced into the postsynaptic neuron during current-clamp
recording and the effects on LTP measured. There was no
significant difference in the amplitude of EPSPs across all
of the conditions at time 0 (one-way ANOVA, p 
0.14783). When vehicle was introduced into the postsyn-
aptic cell, TBS induced robust potentiation (30 min after
the stimulation, EPSP amplitude was 3.31 	 1.32 the
baseline amplitude, n  7; Fig. 9B,F). This potentiation
was NMDA receptor-dependent as it was abolished by
the NMDA receptor antagonist L689,560 (5 M, 0.53 	
0.14 the baseline EPSP amplitude after 30 min, n  3;
Fig. 9B,F). In initial experiments, we found that oTau (444
continued
amplitude of the 1st EPSP remains the same. There is little change in the degree of depression over time. E, Graph plotting the
average relative amplitude of EPSPs (relative to the 1st EPSP) against number in the train at 0–10 min and at 30–40 min with oTau
present in the presynaptic cell. There was a significant increase in depression between 0 and 30–40 min for the 2nd EPSP 2 (p 
0.0347), 3rd EPSP (p  0.0365), and 4th EPSP (p  0.00941) in the train. F, Example EPSP waveforms from a single recording when
oTau was introduced into the presynaptic cell. Averages were constructed at 0–10 min (left panel) and at 30–40 min (right panel) and
are normalized so the amplitude of the 1st EPSP remains the same. The 3rd to 5th EPSPs (arrows) are absent in the 30- to 40-min
average although the action potentials did not fail in the presynaptic cell. G, Graphs plotting paired pulse ratio (amplitude of 2nd
EPSP/amplitude of 1st EPSP) for cells with vehicle present and for recordings when oTau was introduced into the presynaptic cell.
The points are means from single experiments and the bars show the mean and SEMs for all recordings. In both treatments there was
a significant fall in the paired-pulse ratio over the duration of the recording (vehicle p 0.0316 and oTau p 0.0347). H, Graph plotting the
percentage recovery in EPSP amplitude measured by evoking an EPSP 1 s after the end of the train. If there was 100% recovery, then the
recovery EPSP has the same amplitude as the 1st EPSP. The amount of recovery decreases over time and is similar for cells with either
vehicle or oTau introduction. Right panel, Waveforms after 30–40 min (same recording as in F) showing the absence of the 3rd to 5th
EPSPs, but there is some recovery in transmission after a 1-s interval (inset shows mean recovery EPSP). P  0.05, P  0.01.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
Figure 8. Introduction of oTau into postsynaptic neurons has no significant effect on basal synaptic transmission. A, Diagram of
experimental protocol: vehicle was introduced into the presynaptic cell and oTau (666 nM) was introduced into the postsynaptic cell.
B, The amplitude of the 1st EPSP in the train (relative to the amplitude of averaged EPSPs over the first 10 min of the recording) plotted
against time with oTau present in the postsynaptic cell. There was no significant change in the amplitude of the 1st EPSP amplitude
in the train for the duration of recordings. C, Examples of averaged EPSPs (first in train) at different time points throughout the
recording (oTau present in the postsynaptic cell). The EPSP averages have been deconvolved, cropped, and then reconvolved (as in
Fig. 6). D, The mean amplitude of the 2nd to 5th EPSPs in the train normalized to the amplitude of the 1st EPSP in the train, averaged
at 0–10 min and at 30–40 min. There was no significant change in the degree of short-term depression over that time period. E,
Average EPSP waveforms from a single recording where oTau was introduced into the postsynaptic cell. Averages were constructed
at 0–10 min (left panel) and at 30–40 min (right panel) and are not normalized.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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Figure 9. Introduction of oTau into the postsynaptic neuron blocks the induction of LTP. A, Diagram of experimental methods to
measure LTP. EPSPs were recorded in CA1 hippocampal pyramidal cells in response to Schaffer collateral stimulation. LTP was
induced by TBS. B, Mean EPSP amplitude plotted against time for seven slices in control (vehicle introduced into pyramidal cells) and
in three slices where the NMDA receptor antagonist L689,560 (5 M) was present. TBS evoked robust potentiation in control
conditions which was abolished by L689,560. Inset, Average waveforms before (1) and 30 min after (2) TBS in control conditions and
in the presence of L689,560 (5 M). C, Mean EPSP amplitude plotted against time for seven slices with oTau (444 nM) present in the
intracellular recording solution. LTP was abolished. Inset, Average waveforms before (1) and 30 min after (2) TBS. D, Mean EPSP
amplitude against time for five slices with oTau (44 nM) present in the intracellular recording solution. LTP was abolished but there
is some short-term potentiation. Inset, average waveforms before (1) and 30 min after (2) TBS. E, Graph plotting mean EPSP
amplitude against time for five slices with monomeric Tau (444 nM) present in the intracellular recording solution. LTP was induced
in the presence of monomeric Tau. Inset, average waveforms before (1) and 30 min after (2) TBS. F, Summary. In control conditions
(vehicle in the intracellular solution) after 30 min following TBS, EPSP amplitude was potentiated to 3.31 	 1.32 baseline amplitude
(n 7). This potentiation was lost in the presence of L689,560 (0.53	 0.14, n 3), with oTau 444 nM in the intracellular solution (0.989
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nM) abolished both short term potentiation (STP) and LTP
(n  7 slices; Fig. 9C,F). The experiments were repeated
with a 10-fold reduction in the concentration of oTau (44
nM), which also abolished LTP but did not prevent STP (n
 5; Fig. 9D,F). Monomeric tau (444 nM) had little effect
on the degree of potentiation (LTP or STP, n  5; Fig.
9E,F). This indicates that the presence of oTau in post-
synaptic cells will interfere with synaptic plasticity which
could relate to early changes in learning behavior. One
possible mechanism for this interference with plasticity is
a change in the voltage response to the TBS leading to a
subthreshold depolarization. To investigate this possibil-
ity, we examined the TBS voltage responses and found
that there was large variability in response to TBS within
control recordings (vehicle in the postsynaptic cell). There
were some responses where the postsynaptic cell did not
fire, where the cell fired repeatedly across all the bursts
and where the cell only fired in response to the first burst.
However, robust LTP was produced in all cases. We
observed a similar range of responses across all of the
conditions, with no correlation between LTP size and
firing pattern (Fig. 9G). Therefore, it appears unlikely that
a reduction in stimulus-response can account for the loss
of LTP and also because the oTau is only in the postsyn-
aptic cell it can be accounted for by impairment of basal
synaptic transmission.
The effects of oTau on synaptic transmission and LTP
strongly suggest that oTau must reach synaptic locations.
To investigate this, we fully reconstructed a subset of four
hippocampal neurons in which 444 nM oTau was intro-
duced into the soma via a patch pipette and recordings
were made for 20 min. In these neurons, puncta of oTau
could clearly be observed in the distal dendrites (up to the
bifurcation) and could also be observed in the axon (Fig.
9H). This indicates that the introduced oTau can spread
from the soma into dendritic and axonal compartments in
20 min and is consistent with the effects on neurophys-
iology.
Discussion
This is the first study to investigate the effects of intro-
ducing oligomeric tau protein (oTau) directly into the soma
of mammalian neurons in acute brain slices and then
using whole-cell patch clamp recording to investigate the
resultant changes in electrophysiological properties and
synaptic transmission.
In several previous studies, tau oligomers have been
applied to brain slices and neuronal cultures via the ex-
tracellular media (Lasagna-Reeves et al., 2012; Booth
et al., 2016; Fá et al., 2016; Puzzo et al., 2017). Although
tau has clear effects in these studies, it is difficult to
determine whether tau is acting on the outside of neurons,
to quantify how much tau is taken up into neurons and
whether the observed effects on synaptic transmission
are pre or postsynaptic. Transgenic models of tauopa-
thies have also been used to investigate changes in neu-
ronal properties produced by tau (Rudinskiy et al., 2014;
Zhou et al., 2017; McInnes et al., 2018). In these studies,
it is difficult to measure the concentration of oTau present
and the specific oTau conformers that mediate the toxic-
ity. The successful use of patch clamp electrodes to
introduce characterized -synuclein oligomers into mam-
malian neurons has been published previously (Kaufmann
et al., 2016). Here, using the same strategy, we have
measured the time-dependent and concentration-depen-
dent effects of oTau. A major difference between our
study and previous studies (apart from the method of
introducing tau oligomers) is that only one neuron in a
network will be affected by the introduced tau. This
means that any changes in electrophysiological proper-
ties that are measured are direct and do not arise from
compensatory changes in networks that may occur if the
properties of many neurons are affected. Other major
advantages of our approach include using the neuron (at
whole-cell breakthrough) as an internal control for each
recording and the removal of any slow cellular uptake
steps which maybe present when tau is applied extracel-
lularly. Furthermore, this method only requires a small
amount of oTau and allows the targeting of oTau into
either pre or postsynaptic neurons.
We used a method to prepare oTau which did not
involve any inducers (such as heparin, RNA, etc.), as they
may potentially produce cellular effects themselves. We
have used Alexa Fluor 488 to label and also to limit the
aggregation to oTau into fibrils. While an obvious caveat
to this method is that we have mutationally altered tau-
441, CD spectral analysis shows the mutations and label-
ing have only minor effects on tau structure (Fig. 1E). More
importantly, we have now established a proof of principle
in the successful performance of these studies that in the
future can be extended for in-depth analysis of different
oTau preparations including tau with clinically relevant
mutations. The oTau we prepared had a granular/spheri-
cal structure and a predominant -sheet conformation
(Fig. 1). The oTau reacted strongly to the T22 oligomeric
tau antibody, the HT7 mid-region tau antibody and the
K9JA tau repeat domain-binding antibody. We have
continued
	 0.31, p  0.042, n  7, control vs 444 nM) and with 44 nM oTau in the intracellular solution (1.11 	 0.1, n  5). In contrast
potentiation persisted with mTau (444 nM) in the intracellular solution (3.35 	 0.90, n  5). One-way ANOVA gives a significant effect
of treatment (F(4,22)  5.645, p  0.0028) and Fisher post hoc comparisons shows significant differences between the potentiation
of cells injected with vehicle and L689,560, 44, or 444 nM oTau (p  0.0055, p  0.0077, and p  0.0018, respectively). G, Example
voltage responses to the first burst in the TBS for a neuron where vehicle was introduced, where 444 nM oTau was introduced and
where 44 nM oTau was introduced. H, Photomicrographs of the dendrite bifurcation from a labeled hippocampal neuron where 444
nM oTau was introduced at the soma. Left panel, Dendrites labeled with Alexa Fluor 594 introduced from patch pipette. Middle panel,
Fluorescent puncta of oTau. Right panel, Merged image showing dendrites (red) and oTau puncta (green). Scale bar 12 M. P  0.01.
Figure Contributions: Emily Hill performed the experiments and analyzed the data.
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confirmed that the tau preparations used for electro-
physiological analysis were oligomeric, bearing the
aggregation-defining repeat domain and a clinically rele-
vant mid-region epitope used in biomarker tests for
tauopathies (Chen et al., 2019). The tau oligomers were
diluted into the intracellular solution after filtering to pre-
vent binding to the filter and loss of protein (Fig. 1). Clearly
the tau could oligomerize in vitro, although it was not in a
hyperphosphorylated state. In contrast hyperphosphory-
lation has been implicated in the oligomerization process
that occurs in vivo (Avila et al., 2006; Qiang et al., 2018).
Taken together this suggests that the hyperphosphoryla-
tion may be required for the dissociation of tau from the
microtubules in vivo but not for the oligomerization step.
One interesting question is what is the phosphorylation
state of the tau oligomers once they have been introduced
into the neurons? Since the oligomers were un-phos-
phorylated before their introduction into neurons, any
changes in the phosphorylation status post introduction
(whether to the introduced oligomers or endogenous tau)
might play a role in the mechanism of the observed
effects. Experiments on phospho-tau status are often
reported using Western blottings and densitometry. How-
ever, this is not a feasible way to determine tau phosphor
status, using our single cell introduction method. More
recently new mass spectrometric assays have been de-
veloped (Barthélemy et al., 2019) but, again, require sub-
stantial material to determine changes in phosphor status.
Furthermore, the full-length oligomers used in this study
contain around 80 epitopes that can be phosphorylated.
While specific phospho-Ser/Thr/Tyr antibodies are avail-
able for several of these, it is unlikely that a single cell
immunofluorescence analysis will yield interpretable re-
sults.
The effects of tau oligomers are not due to
accumulation of aggregates in pipette or in area of
whole-cell breakthrough
A number of control experiments were used to validate
that the effects of oTau introduction were specific and not
an artifact of the recording and introduction protocol.
There was no significant difference in the electrophysio-
logical parameters following the introduction of vehicle
(buffer without tau) or the addition of a similar size
aggregation-competent molecule, BSA (20 M). It is con-
ceivable that either the narrow tip of the patch-pipette
becomes clogged with aggregated tau or tau accumu-
lates in the soma around the breakthrough site leading to
filtering of the signals (particularly the action potential).
Three pieces of experimental evidence makes this seem
unlikely. Firstly, there was no difference in either the initial
series resistance across the conditions and no significant
increase in series resistance for the duration of the re-
cordings (Fig. 5D). Secondly, in re-patching experiments,
the changes in action potential amplitude and kinetics
persisted when the cells were re-patched with intracellular
solution containing vehicle. Finally, when oTau was intro-
duced into the postsynaptic cell, it had no effect on the
amplitude or kinetics of the recorded EPSPs. If the effects
of oTau were simply a filtering effect, then the EPSP
amplitude would be expected to decrease and EPSPs
would also have slower rise and decay kinetics. It has
been shown before that -synuclein oligomers (at a sim-
ilar concentration, 500 nM), which were injected into cor-
tical neurons, had no effect on action potential amplitude
and the action potential rise and decay kinetics were not
slowed (Kaufmann et al., 2016). This suggests that the
introduction of aggregating oligomeric species does not
produce generalized filtering effects per se.
Tau oligomers modify action potential amplitude and
kinetics but have little effect on subthreshold
properties
Using standard step and dynamic currentvoltage re-
sponses, we found that oTau had little effect on the
majority of the subthreshold parameters that were mea-
sured. It was only at late time points (after 40 min) and
with the larger concentrations of oTau (444–666 nM) that
significant changes in input resistance (increased) and
membrane potential (depolarized) occurred leading to an
increased action potential firing rate. It may be that lower
concentrations of oTau (44–133 nM) would eventually
have effects on input resistance and membrane potential
if the recordings lasted long enough (a small increase in
firing rate was observed at late time points for six out of
seven cells with 133 nM oTau). An increase in input
resistance could result from the block of a standing (or
leakage) conductance or possibly from the electronic
conversion of the cell from multi compartments to a single
compartment by reducing current flow. The oTau-induced
depolarization is consistent with previously reported data
from the rTg4510 mouse model, which expresses human
tau variant P301L, where the pyramidal cells are depolar-
ized by 8 mV compared to WT littermates (Rocher et al.,
2010).oTau markedly altered the action potential wave
form causing a slowing of rise and decay kinetics and a
reduction in peak amplitude. These effects were concen-
tration dependent, occurring more rapidly with larger con-
centrations of oTau and did not occur with tau monomers.
The mechanism underlying these changes in action po-
tential wave form are currently not clear. It is possible that
the aggregation of oTau in the soma act as a barrier to
current flow from the initial segment in the axon (where
Na channels are concentrated) to where the action po-
tential is recorded in the soma or it could be due to
changes in voltage gated Na or K channels.
Presynaptic tau oligomer injection impairs synaptic
transmission
The introduction of oTau into the presynaptic neuron
led to a large reduction in synaptic strength, an effect
which was not observed when oTau was introduced into
the postsynaptic neuron or if vehicle was introduced into
both presynaptic and postsynaptic neurons. An inhibition
of synaptic transmission has been previously reported in
transgenic tau models (Zhou et al., 2017; McInnes et al.,
2018). The inhibition of transmitter release by the activa-
tion of presynaptic receptors (such as adenosine A1 or
GABAB) is associated with an increase in paired-pulse
ratio and a reduction in depression across a train of
EPSPs (Kerr et al., 2013). This contrasts with the inhibitory
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effects of oTau which were not associated with a de-
crease in depression across a train of stimuli. In many of
the recordings, the later EPSPs in the train failed, although
there was some recovery of transmission following a 1-s
interval. It has been reported in synapses between cul-
tured hippocampal neurons from transgenic mice ex-
pressing tau that synaptic depression is enhanced and
that this results from the crosslinking of vesicles with actin
to slow vesicle movement (Zhou et al., 2017). Our data are
consistent with a reduction in the rate of vesicle restock
although this does not account for the change in the first
EPSP.
Does the change in action potential wave form contrib-
ute to the inhibition of synaptic transmission? Injection of
human tau into the squid axon has been shown to result
in inhibition of synaptic transmission without changing the
action potential wave form Moreno et al. (2016), suggest-
ing that tau can directly affect the release machinery in the
synaptic terminal. It is possible that the changed dynam-
ics of the action potential wave form interferes with prop-
agation down the axon to the release sites, leading, for
example, to branch-point failure. This, however, seems
unlikely, as it has been previously shown that complex
spikes consisting of two to three full sized action poten-
tials followed by several highly attenuated “spikelets” are
all fully propagated down the axon of CA1 pyramidal cells
(Apostolides et al., 2016).
Postsynaptic oTau disrupts LTP
Introduction of either 44 or 444 nM oTau into postsyn-
aptic hippocampal neurons prevented the induction of
LTP, with 444 nM also abolishing short-term potentiation.
These effects were not observed when either vehicle or
monomer (444 nM) was introduced into postsynaptic neu-
rons. Previous studies have shown that extracellular oTau
can impair LTP (Lasagna-Reeves et al., 2012; Fá et al.,
2016) with monomeric tau inactive. In these experiments,
oTau was introduced via the extracellular medium and
thus it is unclear whether the site of action was either
presynaptic or postsynaptic or there was activity at both
sites. Ondrejcak et al. (2018) demonstrated that for a
subset of AD brain extracts, that produced amyloid
-independent reductions in LTP, immunodepletion of the
extract with the Tau5 monoclonal antibody prevented the
impairment of LTP. These studies provide a strong argu-
ment for testing the effect of direct neuronal oTau intro-
duction on LTP. Our study validates the results of
previous studies and also provides direct evidence that
the postsynaptic effects of oTau are sufficient to abolish
LTP. The observed defects in LTP could result from oTau
increasing the threshold for LTP induction or by blocking
LTP induction mechanisms. The former could be the re-
sult of oTau changing the voltage response to the TBS so
that insufficient depolarization reaches the dendritic
spines to remove the NMDA receptor Mg2 block. Al-
though this possibility cannot be completely ruled out, it
appears unlikely as there were no consistent changes in
TBS voltage responses and the responses were highly
variable under control conditions. Recent experiments
have highlighted the importance of tau in plasticity (Regan
et al., 2015) with its correct phosphorylation required for
long-term depression. It is possible that the introduced
oTau could bind or sequester the tau present in the
dendrites leading to inhibition of plasticity.
Following whole-cell recordings (up to 40- to 50-min
duration), fluorescent oTau could be clearly observed in
both the cell body of CA1 hippocampal pyramidal cells
and also in the distal dendrites and axons. This is consis-
tent with the observed effects of oTau on synaptic trans-
mission and plasticity.
Concluding statement
Using a targeted approach, we have introduced oTau
into cortical neurons and have shown rapid changes in
electrophysiological properties, synaptic transmission
and synaptic plasticity.
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